Navigation Links
New drug combination therapy developed to treat leukemia
Date:4/17/2013

A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins. The effectiveness of the therapy lies in its ability to target a pro-survival cell signaling pathway known as PI3K/AKT/mTOR, upon which the leukemia cells have become dependent.

In the study, published in the journal Cancer Research, researchers combined the drug ABT-737 with another agent BEZ235. ABT-737 targets proteins known as B-cell lymphoma 2 (Bcl-2) and Bcl-xL, which prevent apoptosis, a form of cell suicide, in cancer cells. BEZ235 directly inhibits the PI3K/AKT/mTOR pathway, and as a result, reduces the expression of another anti-apoptotic protein known as Mcl-1, which is not targeted by ABT-737. Among their many functions, signaling pathways regulate biological processes required for cellular survival. The PI3K/AKT/mTOR pathway helps keep apoptosis in check, in part, by controlling the production of Mcl-1. However, the pathway can become dysregulated in cancer, and in so doing, contribute to uncontrolled tumor growth and resistance to conventional cancer therapies. It is activated in 50 to 80 percent of patients with acute myelogenous leukemia (AML), and in some, but not all cases, is associated with genetic mutations. Significantly, disabling both anti-apoptotic proteins, Bcl-2 and Bcl-xL, in conjunction with Mcl-1, caused profound cell death of leukemia cells in the test tube as well as in animal models of AML.

"This study builds on many years of work in our laboratory investigating the mechanisms that regulate apoptosis in human leukemia cells. To the best of our knowledge, it is the first to raise the possibility that activation of the P13K/AKT/mTOR pathway, rather than genetic mutations within the pathway, may represent the best predictor of leukemia cell responses to these targeted agents," says one of the study's key researchers Steven Grant, M.D., Shirley Carter Olsson and Sture Gordon Olsson Chair in Oncology Research, associate director for translational research, program co-leader of Developmental Therapeutics and Cancer Cell Signaling research member at VCU Massey Cancer Center. "These findings could lead to a new therapeutic strategy for patients with AML and potentially other diseases by targeting patients whose leukemia cells display activation of a specific survival pathway."

Grant's team made another discovery that helped explain the new therapy's effectiveness. They found that the therapy releases and/or activates the pro-apoptotic proteins Bim, Bak and Bax, which help trigger apoptosis. Thus, in addition to disabling major pro-survival proteins, the combination therapy also helps to unleash several additional proteins that promote apoptosis.

Moving forward, Grant and his team hope to work with pharmaceutical companies and the National Cancer Institute to develop strategies combining inhibitors of the PI3K/AKT/mTOR pathway with Bcl-2 family antagonists for the treatment of patients with AML.


'/>"/>

Contact: Alaina Farrish
akfarrish@vcu.edu
804-628-4578
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. Immunotherapy for elderly cancer patients finds new promise in drug combination
2. Combination of 2 drugs reverses liver tumors
3. Cancer vaccine combination therapy shows survival benefit in breast cancer
4. Discovery suggests new combination therapy strategy for basal-like breast cancers
5. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
6. BUSM in vitro study identifies potential combination therapy for breast cancer
7. DNDi and Cipla to develop 4-in-1 pediatric antiretroviral drug combination
8. Combination peptide therapies might offer more effective, less toxic cancer treatment
9. Drug combination against NRAS-mutant melanoma discovered
10. Combination treatment may improve survival of breast cancer patients with brain metastases
11. Scientists test 5,000 combinations of 100 existing cancer drugs to find more effective treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ... of a new report from the Frank Hawkins Kenan Institute of Private ... business leaders, academics and policy makers identified concrete solutions at the “What’s Next, ...
(Date:1/24/2017)... ... January 24, 2017 , ... The results from the ... and particularly good news for prostate cancer patients: incidents of cancer is down as ... the report the cancer death rate has dropped from its peak of 215.1 in ...
(Date:1/24/2017)... ... January 24, 2017 , ... American Family Care (AFC) has opened a new ... care for residents in the area. The Bedford clinic will be the nineteenth location ... years by Dave Adams and Dr. Kristina Orio. Adams and Orio also independently own ...
(Date:1/24/2017)... Overland Park, KS (PRWEB) , ... January 24, ... ... rating to Premensa, a leading natural supplement for relieving premenstrual syndrome, or ... premenstrual syndrome at some point. These symptoms can include cramps, constipation, irritability, headaches, ...
(Date:1/24/2017)... ... 2017 , ... “Who Would Have Dreamed: A Novel of Miracles”: a beautiful and poignant ... understand its purpose in her life. “Who Would Have Dreamed: A Novel of Miracles” is ... love of writing. , Sharon shares that she started her spiritual journey later ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Oregon and PUNE, India ... new report published by Allied Market Research, titled, "Cold ... Bakery & Confectionary, Dairy & Frozen Dessert, Meat, Fish ... Global Opportunity Analysis and Industry Forecasts, 2014-2022," projects that ... garner $426,275 million by 2022, growing at a CAGR ...
(Date:1/24/2017)... 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ... 40 finalists in the Regeneron Science Talent Search, the ... for high school seniors. Finalists were selected based on ... projects. The finalists will now go to ... to undergo a rigorous judging process to determine the ...
(Date:1/24/2017)... , Jan 24, 2017 Research and Markets ... Analysis and Trends - Product, Material - Forecast to 2025" ... ... grow at a CAGR of around 5.4% over the next decade ... the prominent trends that the market is witnessing include 3D medical ...
Breaking Medicine Technology: